April 15th, 2016, Shenzhen, China – BGI, one of the world’s largest omics organizations, announced today that it has performed more than 1 million NIFTY® tests worldwide.
The NIFTY® test is a highly accurate non-invasive prenatal test (NIPT) that screens for chromosomal aneuploidies, including trisomies 21, 18 and 13, from as early as week 10 of pregnancy. NIFTY® provides a significantly stronger risk indication than traditional screening procedures. With a validated sensitivity rate of >99% and a false positive rate of 0.1% for trisomies 21, 18 and 13, NIFTY® ensures that the number of women undergoing unnecessary invasive diagnostic procedures is significantly reduced. The NIFTY® test is currently offered in more than 62 countries across the world.
BGI was founded in 1999 as part of its participation in the Human Genome Project. Over the years, BGI has grown into a multinational company with significant global operations. With more than 5,000 employees across the globe and R&D, manufacturing, and commercial operations around the world, BGI is committed to providing solutions to address the research, pharmaceutical, and clinical markets. BGI’s focus has centered on improving human health and empowering large-scale human, plant, and animal genomics research.